Strategies for navigating the regulatory, manufacturing, sales and marketing route to biosimilar market entry. 11 - 13 September 2012, Jumeirah Carlton Tower, London, UK Get competitive insight into global regulatory strategies, and find out how to successfully bring biosimilars to-market in developed and developing regions...
â?¨As biopharmaceutical patents are beginning to expire, biosimilar products are starting to enter the marketplace. To date the EMEA has approved 14 biosimilars for use in the EU and has issued an established regulatory pathway for ... Read Post
Biosimilar development costs are high with some industry leaders claiming estimates of $100-150 million. Even after this substantial investment there is no guarantee of immediate return. With the FDA, America's regulatory body, stru... Read Post